The ADMIRE network organizes a virtual lecture series that aims to strengthen the exchange between scientists working on aldosterone, the mineralocorticoid receptor, or related topics worldwide. The forum is open ...

Epigenetic modulators have been proposed as promising new drug targets to treat adverse remodeling in heart failure. Here, we evaluated the potential of 4 epigenetic drugs, including the pan-BRD (bromodomain-containing ...

During the past few years enormous research activities substantially advanced our understanding of the molecular, cellular, and pathophysiological functions of the MR. The British Journal of Pharmacology now publishs a ...

MR antagonists have proven to be highly efficient in patients with heart failure and reduced ejection fraction, and they are a cornerstone of contemporary therapy. In the past decade, a series of ...

The German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) supports the formation of a scientific network on ‘Strategies for therapeutic targeting of the Aldosterone-Mineralocorticoid Receptor signaling pathway’ (Speaker: Achim Lother). The network ...

Mineralocorticoid receptor antagonists (MRAs) are highly effective therapies for cardiovascular and renal disease. However, the widespread clinical use of currently available MRAs in cardiorenal medicine is hampered by an increased ...